TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03324568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Education Videos
Description: Participants will receive educational videos describing behavioral techniques to improve parent and child eating behavior.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Handout
Description: Participants will receive educational handouts describing behavioral techniques to improve parent and child eating behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Handout
Description: Participants will receive educational handouts describing behavioral techniques to improve parent and child eating behavior.
Study: NCT03688308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with bone marrow aspirate concentrate
Description: Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique. Subjects will also be injected with bone marrow aspirate concentrate harvested from the pelvis and centrifuged prior to injection in the shoulder (produced using the Harvest/Terumo BCT system)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique.
Study: NCT02320305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 Antigen
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 Antigen
Description: Given IM
Study: NCT02685254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural skills training group
Description: Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
Study: NCT02320305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR4 Agonist GLA-SE
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00302848

Intervention type: DRUG
Intervention: Drospirenone

Intervention type: DRUG
Intervention: Levonorgestrel

Intervention type: DRUG
Intervention: Other progestin containing oral contraceptive
Study: NCT00726856

Intervention type: DRUG
Intervention: Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate
Description: Ezetimibe 10 mg taken daily for 3 months
Study: NCT04404543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1807
Description: Escalation Cohort Administration: Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1807
Description: Dose Expansion Cohort Administration: Orally
Study: NCT03682094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
Study: NCT04601155

Intervention type: DEVICE
Intervention: AlloSure
Description: AlloSure is an analytically validated targeted next-generation sequencing (NGS) assay that uses single-nucleotide polymorphisms (SNPs) to measure the fraction of dd-cfDNA in transplant patients without the need for genotyping either the donor or the recipient.8
Study: NCT00244075

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplement
Description: either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplement
Description: either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human growth hormone (rcGH)
Description: subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
Study: NCT03903133

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin E
Description: vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
Study: NCT04196400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroid betamethasone
Description: The steroid is injected using insulin needle in the subcutaneous tissue after finishing the repair
Study: NCT01930773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genotyping
Description: Patients harboring CYP2C19 \*2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
Study: NCT03768219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210
Study: NCT01930773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phenotyping
Description: Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
Study: NCT04834323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: distal mesogastric fixation after sleeve gastrectomy
Description: Investigators performed traditional laparoscopic sleeve gastrectomy then we fixed the greater omentum \& mesocolon that were cut during gastrectomy to the remaining gstric pouch along the new greater curvature as high as possible along the stable line then we plicated the remaining staple line till angle of His. (the greater omentum \& mesocolon not reach this part of staple line) , so the remaining gastric pouch remained tension free and was returned to original position and this may prevent the axial gastric rotation
Study: NCT03222518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: 14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: 14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol-NSAID
Description: 21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol-NSAID
Description: 21 identical pills of paracetamol ith a preconised dose of 1 pill 3 times per day over 7 days period+14 pills of piroxicam 20 mg are provided with a preconised dose of 1 pill 2times per day over 7 days period
Study: NCT02129738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric catheters
Description: LoFric single use catheters to be used 4-6 times daily for 4 weeks.
Study: NCT02508480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photovoice
Description: The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Control
Description: The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
Study: NCT03780764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A Pre-adjusted edgewise brackets: 3M Gemini Unitek, 0.022 Roth prescription brackets
Description: A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and tied with elastomers (figure of 8).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self- ligating brackets: Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets
Description: Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and held in place by bracket's gate in the self-ligating brackets side.
Study: NCT00077025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
Study: NCT01840423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-104
Description: ODM-104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entacapone
Description: entacapone + levodopa/carbidopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: entacapone + levodopa/carbidopa
Study: NCT03570294

Intervention type: DRUG
Group type: OTHER
Intervention: Atosiban
Description: The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
Study: NCT02999776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser microporation alone
Description: The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care-daily administration of Daivobet
Description: The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laser microporation + topical application of Etanercept
Description: Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
Study: NCT03305016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon hGH
Description: Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
Study: NCT02205710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Computerized games
Study: NCT03667053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: glucagon analog

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for dasiglucagon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucaGen HypoKit
Description: native glucagon
Study: NCT02700282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backpack Carrying
Description: A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Backpack Carrying
Description: A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
Study: NCT04589923

Intervention type: DEVICE
Intervention: Lifelight® Data Collect Blood Pressure Group
Description: The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.

Intervention type: DEVICE
Intervention: Lifelight® Data Collect Oxygen Saturation Group
Description: The staff member will prepare for and take the participant's routine observations using standard clinical equipment during the same 60-second period that video is captured of the participant's face using Lifelight® Data Collect (from which only the RGB data will be uploaded to the cloud). These measurements and RGB data capture will be repeated two times following the initial observations. Once measurements are concluded, the study staff member will complete the post-measurement observation questions.
Study: NCT01495767

Intervention type: OTHER
Intervention: Filling in a psychometric questionnaire
Description: Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
Study: NCT01621217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Will be given weekly intravenously during study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Will be given intravenously twice together with 5-Fluoruracil during study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoruracil
Description: Will be given intravenously twice together with Mitomycin C during study treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
Study: NCT02289131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing Protocol
Description: A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing Protocol
Description: A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Brushing Protocol
Description: A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
Study: NCT01415791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1
Study: NCT03813329

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified Sodium Bicarbonate
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Sodium Bicarbonate
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Modified Sodium Bicarbonate
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acute Sodium Bicarbonate
Description: 3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute Sodium Bicarbonate
Description: 3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Acute Sodium Bicarbonate
Description: 3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate (placebo)
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (placebo)
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate (placebo)
Description: 4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
Study: NCT02501304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReVENT Sleep Apnea System
Description: The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
Study: NCT03647501

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody cage (titanium)
Description: Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody cage (PEEK)
Description: Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
Study: NCT02567435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Given IV
Study: NCT04889833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypnosis therapy
Description: Pre-recorded hypnosis therapy audio recording with accompanying visual of a calm ocean to be played at least once daily for 7 preoperative days, the day of surgery, and for 7 days postoperatively.
Study: NCT01026883

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
Study: NCT01714219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior reconstruction